1. Home
  2. TNXP vs ASPS Comparison

TNXP vs ASPS Comparison

Compare TNXP & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$5.14

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Logo Altisource Portfolio Solutions S.A.

ASPS

Altisource Portfolio Solutions S.A.

N/A

Current Price

$5.62

Market Cap

70.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
TNXP
ASPS
Founded
2007
1999
Country
United States
Luxembourg
Employees
142
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
70.5M
IPO Year
2008
2025

Fundamental Metrics

Financial Performance
Metric
TNXP
ASPS
Price
$5.14
$5.62
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $44.50
N/A
AVG Volume (30 Days)
★ 929.5K
14.3K
Earning Date
11-09-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
★ 112.00
EPS
N/A
★ N/A
Revenue
$13,107,000.00
★ $942,213,000.00
Revenue This Year
$319.65
$16.74
Revenue Next Year
$101.60
$9.32
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 29.85
N/A
52 Week Low
$5.05
$4.30
52 Week High
$20.58
$11.35

Technical Indicators

Market Signals
Indicator
TNXP
ASPS
Relative Strength Index (RSI) 13.33 48.09
Support Level N/A $5.17
Resistance Level $12.99 $6.03
Average True Range (ATR) 0.51 0.38
MACD -0.07 -0.05
Stochastic Oscillator 3.92 35.38

Price Performance

Historical Comparison
TNXP
ASPS

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ASPS Altisource Portfolio Solutions S.A.

Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.

Share on Social Networks: